GSDMD and melanoma: In addition, Decitabine treatment impairs tumor progression in immunocompetent mice and gives rise to a marked increase of both full-length and the cleaved N-terminal fragment of GSDMD in bulk melanomas in vivo (Supplementary Fig. 6h–k), further substantiating a key role of DNMT3A and DNMT1 in transcriptional silencing of GSDMD-mediated pyroptotic pathway in melanoma cells.